Marc de Garidel, the chairman and chief executive of the French pharmaceutical company Ipsen, has been made chairman of the Innovative Medicines Initiative governing board.
De Garidel was appointed at the IMI board meeting, held in Brussels on 24 March. He specialises in neurology, endocrinology and urology-oncology.
The IMI board consists of 10 members, five each from the Commission and the pharmaceutical industry, and is the body responsible for guiding the initiative.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.